Jyong Biotech (MENS) Prices 2.67M Share IPO at $7.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering
June 16, 2025 11:38 PM EDTNew Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the Company), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the pricing of its initial public offering (the Offering) of 2,666,667 ordinary shares (the Ordinary Shares) at a public offering price of $7.50 per share. The Company expects to receive aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses.... More
